Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
Medical References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Both medications contain the same active ingredient, tirzepatide, and are manufactured by the same company
Dizziness is a recognised adverse reaction listed in the Summary of Product Characteristics for several GLP-1 medications
10.1002/ejhf.1858 68 GuoC.SunL.ChenX.ZhangD
US$ 28.80
US$ 22.55
US$ 22.95
US$ 28.45
US$ 20.05
